Uzun M.Yildirim E.C.Ekinci F.Semiz H.S.2024-07-222024-07-2220221022386Xhttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12514Objective: To evaluate the effect of pretreatment C-reactive protein (CRP)/Albumin ratio (CAR) on prognosis and its association with IMDC (International metastatic renal cell carcinoma database consortium) risk score and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey, between 2007 and 2020. Methodology: Clinico-pathological and treatment-related data of mRCC patients were retrospectively evaluated and included in the study. CAR was used as a prognostic inflammatory score. CAR threshold value for OS has been obtained by ROC analysis. The prognostic value of CAR was tested using Kaplan-Meier and Cox-regression models. IMDC-CAR model was created by adding CAR to IMDC risk stratification. Results: OS was 91 months in patients with CAR below the threshold value of 0.072 (0.072), while OS was 51 months in patients with CAR of 0.072 and above (p=0.005). According to IMDC risk stratification, intermediate and poor risk groups showed similar survival times (p0.05). However, when CAR was added to the IMDC risk score in the intermediate group, it was divided into 3 subgroups with different prognoses (p=0.02). Conclusion: CAR is an independent predictor of OS in mRCC patients. In this study, it has been demonstrated that more accurate prognosis prediction could be made by adding CAR to IMDC indicators in the intermediate risk group, which constitutes a highly heterogeneous group according to IMDC risk stratification. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.EnglishAll Open Access; Gold Open AccessC-Reactive ProteinCarcinoma, Renal CellHumansKidney NeoplasmsPrognosisRetrospective StudiesRisk AssessmentalbuminaxitinibC reactive proteinnivolumabprotein tyrosine kinase inhibitorsunitinibC reactive proteinadultagedArticleC reactive protein to albumin ratiocancer patientcancer prognosiscancer riskcancer survivalcancer therapyclinical featurecohort analysiscontrolled studydisease associationevaluation studyfemalehumanhuman cellintermediate risk populationKaplan Meier methodlow risk populationmajor clinical studymalemetastatic renal cell carcinomamiddle agedoncological parametersoverall survivalproportional hazards modelreceiver operating characteristicretrospective studyrisk assessmentsurvival timeTurkey (republic)kidney tumorpathologyprognosisrenal cell carcinomarisk assessmentArticle10.29271/jcpsp.2022.11.1425